- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04901884
PET/MR Evaluación previa y posterior a la radioterapia para la disfunción cardiopulmonar
Evaluación exploratoria de PET/RM cardíaca simultánea, marcadores metabolómicos y ADN circulante como posibles marcadores pronósticos en la identificación de pacientes que desarrollan disfunciones cardiopulmonares transitorias o permanentes después de la radioterapia
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA.
PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH).
Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain threshold of received dose.
To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after RT.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
RT is a well-known and established therapy or adjuvant therapy for the treatment of thoracic malignancies (breast cancer, lung cancer, lymphoma and others). It usually uses high energy radiation from x-rays, gamma rays or other charged particles to induce DNA damage in malignant cells. Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, the signs and symptoms of radiation induced cardiopulmonary dysfunction (RICPD) still persist. However, in the majority of cases, it remains unclear which cardiopulmonary damage is the main /leading cause for the clinical symptoms the patients are experiencing.
Hybrid PET/MRI is a promising technique that allows for truly simultaneous molecular, anatomic and functional imaging of the cardiopulmonary system. The simultaneity is an important aspect in this proposed study since only parameters measured at the same time in PET and MR can be used for an integrated, multimodality parameter for possible detection and prognostication of the different underlying processes of cardiopulmonary dysfunction after RT. Furthermore, certain PET-uptake of the RV have to be corrected for RV mass which is only possible with concomitant anatomical imaging. MR imaging and PET at different time point are not accurately reflective of the underlying pathophysiological pathways and metabolic state at the specific time points pre- and post radiotherapy. To our knowledge, there are no online publications of its use in the diagnosis and prognostication of cardiopulmonary dysfunction after RT and specifically PH.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Patrick Veit-Haibach, MD
- Número de teléfono: 6085 416-340-4800
- Correo electrónico: Patrick.Veit-Haibach@uhn.ca
Copia de seguridad de contactos de estudio
- Nombre: Andrew Hope, MD
- Número de teléfono: 416-946-2124
- Correo electrónico: Andrew.Hope@rmp.uhn.ca
Ubicaciones de estudio
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- Reclutamiento
- University Health Network
-
Contacto:
- Patrick Veit-Haibach
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥18 years
- Biopsy or otherwise clinically proven thoracic malignant mass which is intended to be treated with radio(chemo)therapy
- Intention to treat with radio(chemo)therapy with incidental cardiac irradiation of at least 25Gy.
- A negative urine or serum pregnancy test within the two week interval immediately prior to imaging, in women of child-bearing age.
- Ability to provide written informed consent to participate in the study (for all components of the trial: imaging with cardiac PET/MR, blood sampling for plasma metabolomics and circulating DNA).
Exclusion Criteria:
- Contraindication for MR as per current institutional guidelines.
- Contraindication for Gadolinium injection as per current institutional guidelines.
- Inability to lie supine for at least 45 minutes.
- Any patient who is pregnant or breastfeeding.
- Any patient with known hypersensitivity to 18F-FDG.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: One arm / exploratory study
Injection of 18F-FDG.The 18F-FDG cardiac PET-MR scanning visit will take up to 1.5 hours. |
(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change of FDG uptake of heart
Periodo de tiempo: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
FDG uptake of the left and right ventricles of heart will be measured and compared in PETMRI scans |
at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
|
Change of FDG uptake of lungs
Periodo de tiempo: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
FDG uptake of left and right ratios within the lungs in PETMRI scans |
at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
|
Change of the heart function
Periodo de tiempo: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
MRI of ventricular volumes in PETMRI scans |
at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
|
Change of the lung perfusion
Periodo de tiempo: before radiotherapy and up to 16 weeks after completion of radiotherapy
|
Percentage of the perfused/ventilated lung segments will be evaluated and compared pre and post therapy by SPECT scans |
before radiotherapy and up to 16 weeks after completion of radiotherapy
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Patrick Veit-Haibach, MD, University Health Network, Toronto
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 18-5879
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .